Diekhoff, Torsten http://orcid.org/0000-0003-3593-1449
Deppe, Dominik
Poddubnyy, Denis
Ziegeler, Katharina
Proft, Fabian
Radny, Felix
Niedermeier, Christoph
Hermann, Kay Geert
Makowski, Marcus R.
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 23 September 2023
Revised: 8 January 2024
Accepted: 8 January 2024
First Online: 15 January 2024
Declarations
:
: The institutional review board of the Charité Universitätsmedizin Berlin approved this prospective study under EA1/086/16. All patients gave written informed consent. Patients were not involved in the study planning.
: TD reports lectures for Canon Medical Systems, Novartis, MSD and Roche and advisory board membership for Eli Lilly. DP reports research support from: AbbVie, Eli Lilly, MSD, Novartis, Pfizer; consulting fees from: AbbVie, Biocad, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, MSD, Moonlake, Novartis, Pfizer, Samsung Bioepis, and UCB; speaker fees from: AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, MSD, Medscape, Novartis, Peervoice, Pfizer, and UCB. FP: reports grants and personal fees from Novartis, Lilly and UCB and personal fees from AbbVie, AMGEN, BMS, Hexal, MSD, Pfizer and Roche all outside the presented work. KGAH reports speaker fees from AbbVie, MSD, Pfizer, and Novartis. He is also the co-founder of BerlinFlame GmbH. For the remaining authors no conflicts of interest were declared.